WESTMINSTER, Colo.--(BUSINESS WIRE)--Jul. 22, 2009--
Allos Therapeutics, Inc. (NASDAQ: ALTH), a biopharmaceutical company
committed to the development and commercialization of innovative
anti-cancer therapeutics, today announced that Company management will
provide a corporate update and review of the second quarter 2009 results
via webcast and conference call on Tuesday, August 4, 2009, at 4:30 p.m.
ET.
The webcast of this call will be available from the homepage and the
investors/media section of the Company's Web site, www.allos.com.
Alternatively, callers may participate in the conference call by dialing
888-549-7880 (domestic) or 480-629-9869 (international). Participants
should reference the Allos Therapeutics conference call. Webcast and
telephone replays of the conference call will be available approximately
two hours after the completion of the call through Friday, August 14,
2009. To access the replay, callers should dial 1-800-406-7325
(domestic) or 303-590-3030 (international) and use passcode 4117858#.
About Allos Therapeutics, Inc.
Allos Therapeutics, Inc. (Nasdaq: ALTH) is a biopharmaceutical company
committed to the development and commercialization of innovative
anti-cancer therapeutics. The Company’s product candidate, pralatrexate,
is a selective antifolate designed to accumulate preferentially in
cancer cells. The Company recently announced that the U.S. Food and Drug
Administration (FDA) accepted its New Drug Application (NDA) for
pralatrexate for patients with relapsed or refractory peripheral T-cell
lymphoma for priority review and established a Prescription Drug User
Fee Act date of September 24, 2009 for a decision regarding approval of
the NDA. In addition, pralatrexate is being evaluated in patients with
non-small cell lung cancer, bladder cancer and a range of lymphoma
sub-types. Allos retains exclusive worldwide rights to pralatrexate for
all indications. The Company is headquartered in Westminster, Colo. For
more information about Allos, visit www.allos.com.
Safe Harbor Statement
The 2009 second quarter results press release and conference call will
contain forward-looking statements that involve significant risks and
uncertainties, including those contained in the "Risk Factors" section
of the company's Form 10-Q for the quarter ended March 31, 2009 and in
the company's other periodic reports and filings with the Securities and
Exchange Commission. Allos is providing the information contained in the
press release and conference call as of the date of the release and does
not undertake any obligation to update any forward-looking statements as
a result of new information, future events or otherwise. The Company
cautions investors not to place undue reliance on the forward-looking
statements contained in the press release or the conference call. No
forward-looking statement can be guaranteed and actual events and
results may differ materially from those projected.
Source: Allos Therapeutics, Inc.
Allos Therapeutics, Inc.
Monique Greer, 720-540-5268
mgreer@allos.com
